- Home
- TVTX
as 11-15-2024 4:00pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $23.46 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.12 - $20.33 | Next Earning Date: | 10-31-2024 |
| Revenue: | $203,447,000 | Revenue Growth: | 57.08% |
| Revenue Growth (this year): | 62.45% | Revenue Growth (next year): | 59.30% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LYONS GARY A | TVTX | Director | Oct 4 '24 | Sell | $14.75 | 40,000 | $589,100.78 | 69,821 | |
| Meckler Jeffrey A | TVTX | Director | Sep 30 '24 | Sell | $14.06 | 40,000 | $562,324.00 | 81,000 | |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Sep 10 '24 | Sell | $12.98 | 684 | $8,878.32 | 61,949 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Sep 5 '24 | Sell | $11.52 | 21,125 | $243,360.00 | 361,975 | |
| ROTE WILLIAM E. | TVTX | SENIOR VICE PRESIDENT, R&D | Sep 5 '24 | Sell | $11.52 | 4,387 | $50,538.24 | 84,455 | |
| REED ELIZABETH E | TVTX | SVP, GC & CORPORATE SECRETARY | Sep 5 '24 | Sell | $11.52 | 4,387 | $50,538.24 | 78,633 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Sep 5 '24 | Sell | $11.52 | 2,191 | $25,240.32 | 107,958 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Sep 5 '24 | Sell | $11.52 | 2,490 | $28,684.80 | 74,595 | |
| Inrig Jula | TVTX | CHIEF MEDICAL OFFICER | Sep 5 '24 | Sell | $11.52 | 2,191 | $25,240.32 | 61,949 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Sep 4 '24 | Sell | $9.51 | 514 | $4,887.78 | 74,595 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Exploring Three High Growth Tech Stocks in the United States
GlobeNewswire
4 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5 days ago
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
9 days ago
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire
10 days ago
Travere Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire
13 days ago
Travere Therapeutics to Present at Upcoming Investor Conferences
Simply Wall St.
16 days ago
Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
16 days ago
Travere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ...
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.